[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"noncardiac-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:noncardiac-surgery":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,54,89,115,142,164],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100577740","phase-4-the-choice-of-vasopressor-to-prevent-postoperative-acute-kidney-injury-after-major-non-cardiac-surgery-100577740",false,"NCT06802224","The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery","Norepinephrine vs Phenylephrine as the First-line Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-cardiac Surgery","VEGA-2","Inclusion Criteria:\n\n* Age 18 years or older\n* Surgery under general anesthesia with a surgery duration of 2 hours or more\n* Received intravenous vasopressors during surgery\n\nExclusion Criteria:\n\n* Cardiac surgery\n* Extra-corporeal membrane oxygenation\n* Organ transplantation\n* Obstetric procedures\n* Procedures on the kidney\n* Outpatient procedures\n* Already receiving NE or PE or inotropes before induction of anesthesia (at the time of anesthesia start)\n* American Society of Anesthesiologists physical status classification 5 or 6\n* Patient for whom a local protocol recommends a specific first line vasopressor\n* Most recent documented estimated glomerular filtration rate (eGFR) \\\u003C 15 mL\u002Fmin\u002F1.73m\\^2 or preoperative renal replacement therapy within 60 days before surgery\n* Patients who do not have a preoperative creatinine value within 60 days before surgery\n* Alive patients who do not have a postoperative creatinine value","ALL","18 Years",{"count":20,"type":21},18000,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Low blood pressure, also known as hypotension, is very common during major surgery under general anesthesia. Prolonged or severe hypotension can lead to complications such as kidney injury after surgery that slow down patient recovery. Anesthesiologists commonly administer medications called vasopressors to treat low blood pressure during surgery. These medications help raise the blood pressure back up to a safe range. Two vasopressor medications are commonly used for this purpose: norepinephrine and phenylephrine. Each of these medications has slightly different effects on the heart and blood vessels (cardiovascular system). It remains unknown which of these standard medications is better for treating low blood pressure during surgery. The goal of this clinical trial is to determine which of these two medications is better at preventing injury to the kidneys after major noncardiac surgery as well as other complications such as heart problems. Major surgeries are defined as those lasting at least two hours under general anesthesia. This trial will randomize about ten centers in North America to use either norepinephrine or phenylephrine as the primary medication to treat low blood pressure in adults undergoing major noncardiac surgery. Each hospital will prioritize one of the drugs each month, and the assigned drug will rotate each month at each hospital. No further participant involvement will be required as de-identified data are collected as part of standard medical care.",[27,28,29,30,31,32,33],"Anesthesia","Surgery With General Anesthesia","Noncardiac Surgery","Hypotension During Surgery","Acute Kidney Injury (AKI)","Myocardial Injury After Noncardiac Surgery (MINS)","Vasopressor",[35,36,37,38,39,40],"Norepinephrine","Phenylephrine","Major adverse kidney events","Pragmatic","Cluster randomized","Crossover","RECRUITING","2026-05-20",{"date":44,"type":45},"2026-05-26","ACTUAL",{"date":47,"type":45},"2025-04-01",{"date":49,"type":21},"2028-07",{"name":51,"class":52},"University of California, San Francisco","OTHER",10,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":17,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":22,"phases":66,"briefSummary":67,"conditions":68,"keywords":73,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":88},"100633180","phase-4-impact-of-esketamine-on-delayed-neurocognitive-recovery-in-older-patients-100633180","NCT07523334","Impact of Esketamine on Delayed Neurocognitive Recovery in Older Patients","Impact of Esketamine on Delayed Neurocognitive Recovery in Older Patients Undergoing Non-cardiac Surgery: a Two-center, Dose-exploring Pilot Trial","Inclusion Criteria:\n\n1. Aged \\>=65 but \\\u003C= 90 years;\n2. Scheduled to undergo non-cardiac surgery with an expected duration of \\>= 2 hours under general anesthesia;\n3. Requiring patient-controlled intravenous analgesia (PCIA) after surgery.\n\nExclusion Criteria:\n\n1. Unable to communicate preoperatively due to visual or auditory impairment, language barrier, or severe dementia;\n2. Comorbid with schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis;\n3. Traumatic brain injury or neurosurgery;\n4. Severe hepatic dysfunction (Child-Pugh Class C), severe renal dysfunction (receiving dialysis preoperatively), or American Society of Anesthesiologists physical status classification \\>= Ⅳ;\n5. Expected admission to the Intensive Care Unit with endotracheal intubation after surgery;\n6. Anaphylaxis to esketamine;\n7. Participation in other clinical studies, or any other conditions that are considered unsuitable to be involved in the study.",true,"65 Years","90 Years",{"count":65,"type":21},120,[24],"Esketamine is frequently used during the perioperative period for supplemental analgesia. Small sample size trials showed that subanesthetic dose esketamine may decrease postoperative neurocognitive complications. However, conflicting results exist and optimal dose of esketamine remains to be determined. This dose-exploring pilot trial is designed to evaluate the safety and efficacy of three different perioperative esketamine dosing regimens in older patients undergoing major non-cardiac surgery. The primary purpose is to explore the optimal dosing strategy that produce maximal neurocognitive benefits with minimal adverse neuropsychiatric symptoms.",[69,29,70,71,72],"Elderly","Delayed Neurocognitive Recovery","Postoperative Delirium","Esketamine",[74,75,76,77,72],"Older patients","Noncardiac surgery","Delayed neurocognitive recovery","Postoperative delirium","NOT_YET_RECRUITING","2026-04-09",{"date":81,"type":45},"2026-04-14",{"date":83,"type":21},"2026-04",{"date":85,"type":21},"2026-12",{"name":87,"class":52},"Peking University First Hospital",2,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":100,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":114},"100606462","preoperative-vs-postoperative-revascularization-in-coronary-heart-disease-patients-undergoing-time-sensitive-non-cardiac-surgery-chronos-pci-100606462","NCT07175870","Preoperative vs Postoperative Revascularization in Coronary Heart Disease Patients Undergoing Time-Sensitive Non-Cardiac Surgery (CHRONOS-PCI)","Comparison of Clinical Outcomes Between Preoperative and Postoperative Revascularization in Coronary Heart Disease Patients With Time-Sensitive NOn-Cardiac Surgery: A Multicenter Pragmatic Randomized Controlled Trial (CHRONOS-PCI)","CHRONOS-PCI","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of coronary heart disease with non-emergent indication for PCI confirmed by coronary angiography：\n\n  * Non-ST-elevation acute coronary syndrome (NSTE-ACS) at low or intermediate ischemic risk\n  * Chronic coronary syndrome (CCS) with one of the following anatomical characteristics (see Appendix 1 for definition):\n\n    1. Moderate or severe stenosis of the left main coronary artery\n    2. Multivessel disease involving the ostium of the left anterior descending artery\n    3. Three-vessel disease with ≥70% stenosis in each major epicardial vessel\n* Indication for time-sensitive non-cardiac surgery\n* Planned non-cardiac surgery under general anesthesia in the following surgical departments: thoracic surgery, gastrointestinal surgery, colorectal surgery, hepatobiliary and pancreatic surgery, or gynecology\n* For patients with malignant tumors requiring time-sensitive surgery: written informed consent confirming understanding and acceptance that, if randomized to the \"PCI-first\" group, their tumor surgery will be delayed until 90±14 days after PCI, with acknowledgement of potential risks (e.g., tumor progression, change in resectability)\n* Ability to understand the study requirements and sign written informed consent in the language provided by the research team\n\nExclusion Criteria:\n\n* Age \\>80 years\n* Severe thrombocytopenia (platelet count \\\u003C50×10⁹\u002FL)\n* Cardiogenic shock, severe heart failure (NYHA class IV, Killip class IV, or LVEF ≤35%), malignant arrhythmias (including cardiac arrest, asystole, ventricular fibrillation, or sustained ventricular tachycardia), or other life-threatening conditions requiring resuscitation\n* Moderate-to-severe valvular heart disease, high-grade atrioventricular block, or other severe cardiac\u002Fpulmonary dysfunction incompatible with the planned surgery\n* Planned surgery with extremely high bleeding risk (e.g., intracranial surgery, spinal surgery, retinal surgery)\n* Patients with malignant tumors undergoing non-palliative surgery who are in poor general condition, defined as meeting any of the following:\n\n  1. Karnofsky performance score \\\u003C60\n  2. Eastern Cooperative Oncology Group (ECOG) performance status \\>2\n* Disease stage beyond surgical indications or estimated life expectancy \\\u003C1 year\n* Patients requiring emergency or urgent surgery due to critical illness\n* Severe renal dysfunction: serum creatinine \\>442 μmol\u002FL, GFR ≤30 mL\u002Fmin\u002F1.73 m², or currently on renal replacement therapy\n* Severe hepatic dysfunction: Child-Pugh class C or higher\n* Severe uncontrolled systemic infection\n* Advanced dementia with significant decline in quality of life requiring full-time care and support\n* Systemic thromboembolic disease (e.g., pulmonary embolism) making surgery unsuitable\n* Women who are pregnant, breastfeeding, or planning pregnancy during the study period\n* Severe, uncontrolled comorbid conditions continuously impairing physiological or psychological function\n* Participation in another clinical study within 3 months prior to enrollment\n* Any condition judged by the investigator to interfere with participation or study conduct","80 Years",{"count":99,"type":21},140,[101],"NA","To compare the safety and efficacy of preoperative versus postoperative revascularization strategies in patients with coronary heart disease undergoing time-sensitive non-cardiac surgery.",[104,29],"Coronary Artery Disease","2025-09-14",{"date":107,"type":45},"2025-09-16",{"date":109,"type":21},"2025-10",{"date":111,"type":21},"2029-08",{"name":113,"class":52},"First Affiliated Hospital of Wenzhou Medical University",1,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":22,"phases":125,"briefSummary":126,"conditions":127,"keywords":131,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":114},"100589707","transcutaneous-auricular-vagus-nerve-stimulation-and-quality-of-recovery-after-major-noncardiac-surgery-100589707","NCT06957912","Transcutaneous Auricular Vagus Nerve Stimulation and Quality of Recovery After Major Noncardiac Surgery","Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Quality of Recovery After Major Noncardiac Surgery: A Randomized Trial.","Inclusion Criteria:\n\n1. Aged ≥18 years but \\\u003C85 years.\n2. Scheduled for elective or limited-time noncardiac surgery with expected duration ≥2 hours.\n\nExclusion Criteria:\n\n1. Lesions or infections of the auricle skin.\n2. Recent or long-term use of cholinergic or anticholinergic medications.\n3. Neurosurgery.\n4. Expected mechanical ventilation with intubation for ≥1 day after surgery.\n5. Diagnosed schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis before surgery.\n6. Preoperative left ventricular ejection fraction (LVEF) \\\u003C30%, or those with sick sinus syndrome, sinus bradycardia (heart rate \\\u003C50 beats per minute), atrioventricular block of grade II or above, or implanted pacemaker.\n7. Inability to communicate due to coma, severe dementia, or language barrier before surgery, or unable to cooperate with intervention.\n8. American Society of Anesthesiologists physical status grade \\>IV, or estimated survival \\\u003C24 hours.","85 Years",{"count":124,"type":21},320,[101],"Transcutaneous auricular vagus nerve stimulation (taVNS) is a novel non-invasive neuromodulation technique. Existing evidence suggested that taVNS improves pain management, sleep quality, inflammatory responses, and gastrointestinal recovery after surgery. This study is designed to test the hypothesis that perioperative use of taVNS may improve quality of recovery in patients after major noncardiac surgery.",[128,129,29,130],"Vagus Nerve Stimulation","Transcutaneous Electric Nerve Stimulation","Quality of Recovery",[132,75,133],"Transcutaneous auricular vagus nerve stimulation","Quality of recovery","2025-06-02",{"date":136,"type":45},"2025-06-03",{"date":138,"type":45},"2025-05-13",{"date":140,"type":21},"2026-09",{"name":87,"class":52},{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":122,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":114},"100567679","phase-4-preemptive-analgesia-of-dexmedetomidine-reduces-per-operation-pain-100567679","NCT06671327","Preemptive Analgesia Of Dexmedetomidine Reduces Per-operation Pain","Preemptive Analgesia Of Dexmedetomidine Reduces Per-operation Pain After Noncardiac Surgery","Inclusion Criteria:\n\n* 18 years to 85 years old,\n* body mass index (BMI,calculated as weight in kilograms divided by height in meters squared): 18.5\\~35.\n* ASA (American Society of Anesthesiologists) Grade I- III;\n* Scheduled for non-cardiac surgery undergoing general anesthesia\n* expected duration of operation 0.5\\~3 h.\n\nExclusion Criteria:\n\n* disagreed to participate;\n* body mass index (BMI) of greater 35\n* American Society of Anesthesiologists (ASA) classification 4 or above;\n* previous severe central nervous systemheart, liver, kidney or and lung dysfunction ;\n* diagnosed neuropsychological disorders, that is, schizophrenia, epilepsy, Parkinson's disease, myasthenia gravis，Alzheimer's disease and other autonomic disorders of patients affecting EEG outcomes;\n* comatose, dementia, or language barrier which impeded communication and assessment;\n* history of neurosurgical procedures;\n* Systolic blood pressure continuously lower than 85mmHg or higher than 180mmHg; heart rate continuously lower than 45 times \u002F min; sever arrhythmia need intervation and implantable pacemaker.",{"count":150,"type":21},208,[24],"Background:Preemptive analgesia is the initiation of analgesic regimen before the onset of nociceptive stimulation, preventing the amplification of pain due to peripheral and central sensitization and thereby reducing subsequent pain. Preemptive analgesia of dexmedetomidine (DEX) in the epidural and subarachnoid space can effectively prevent the central sensitization, and significantly reduce the phantom limb pain, residual pain after one year of lower limb amputation.\n\nObjective: To investigate the per-operative effects of DEX preemptive analgesia.\n\nMethod:The patients scheduled noncardiac surgery undergoing general anesthesia were selected and divided into DEX group and Placebo group randmized. The DEX group was continuously pumped at 1.5 μg \u002F(kg·h) for 15 minutes before induction, and 15min after induction. The Placebo group was infused with equal amounts of normal saline.The Coprimary efficacy outcome was a composite of analgesia effect, one is the Compliance Rate of IOC2 target in intra-operation, another is the the rate of none-to-slight post-operative pain assessed with the p-NRS≦3 at 12 hours after surgery \\[Pain numeric rating scale was assessed with the (Numeric Rating Scale, p-NRS)\\].",[154,29],"Pain Management","2025-04-07",{"date":157,"type":45},"2025-04-09",{"date":159,"type":21},"2025-04-03",{"date":161,"type":21},"2025-06-30",{"name":163,"class":52},"China International Neuroscience Institution",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":17,"minAge":171,"maxAge":4,"enrollmentInfo":172,"targetDuration":174,"studyType":175,"phases":4,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":114},"100501668","prediction-of-vascular-events-after-major-non-cardiac-surgery--an-observational-prospective-cohort-study-100501668","NCT05812248","Prediction of Vascular Events After Major Non-Cardiac Surgery : an Observational Prospective Cohort Study","PREVENGE-CB-2","Inclusion Criteria:\n\n* Age ≥ 45 years;\n* Undergoing major noncardiac surgery (expected procedure duration ≥2 h, expected length of postoperative stay ≥2 d);\n* History of at least one cardiovascular disease (i.e., coronary artery disease, stroke, congestive heart failure, or peripheral arterial disease) or with at least two cardiovascular risk factors (i.e., hypertension, diabetes, chronic kidney disease, smoking in the past ≥2 years, ≥65 years of age, hypercholesterolemia, history of TIA, high-risk surgery (intrathoracic, intraperitoneal, or major vascular)).\n\nExclusion Criteria:\n\n* History of acute cardiovascular events within 30 days prior to surgery;\n* American Society of Anesthesiologists (ASA) physical status of 5 or greater;\n* Previously enrolled in this study;\n* Unable to understand or to sign informed consent.","45 Years",{"count":173,"type":21},20000,"30 Days","OBSERVATIONAL","This observational study includes patients at medium-to-high cardiovascular risks undergoing major noncardiac surgery, measures their baseline demographic and clinical characteristics, preoperative cardiac biomarkers and intraoperative surgery\u002Fanesthesia related data, and screens them for the occurrence of myocardial injury and major adverse cardiac events after surgery. The primary aim is to develop and validate a pre- and an immediate postoperative prediction model for occurrence of major adverse cardiac events.",[29],"2024-09-03",{"date":180,"type":45},"2024-09-19",{"date":182,"type":45},"2022-07-01",{"date":184,"type":21},"2027-12",{"name":186,"class":52},"Nanfang Hospital, Southern Medical University"]